Objective: Treatment outcomes after salvage re-irradiation in patients with recurrent head and neck cancer vary widely due to heterogeneous patient characteristics, and it is difficult to evaluate optimal re-irradiation schedules. This study aimed to validate a nomogram, originally developed by Tanvetyanon et al., used to predict the survival probability of patients with recurrent head and neck cancer after re-irradiation. Methods: Twenty-eight patients with recurrent head and neck cancer who underwent salvage re-irradiation between June 2007 and November 2011 were evaluated. The median total dose used for initial radiotherapy was 60 Gy (range, 22 -72). Re-irradiation sites included the nasopharynx or Rouviere's node (n ¼ 14), external ear (n ¼ 4), neck lymph node (n ¼ 3) and other sites (n ¼ 7). Overall survival after re-irradiation was calculated using the KaplanMeier method, and the 2-year survival probability was estimated using Tanvetyanon's nomogram. Results: Twenty-two patients were treated with stereotactic body radiotherapy using a median total dose of 30 Gy (range, 15 -40) in 1-7 fractions and six patients were treated with conventional external beam radiotherapy using 45 Gy (range, 23.4 -60) in 10 -30 fractions. The 2-year overall survival was 21.7% (95% confidence interval: 9.3 -41.3), and the 2-year survival probability was 16.8% (95% confidence interval: 9.9 -23.6). The 2-year overall survival in 20 patients with unfavorable prognosis (median 2-year survival probability, 5.5%) and in 8 patients with favorable prognosis (median 2-year survival probability, 45%) were 11.0 and 45.7%, respectively (P ¼ 0.05). Conclusions: Our findings show that Tanvetyanon's nomogram accurately estimates the survival probability in patients with recurrent head and neck cancer after re-irradiation.
INTRODUCTION
About 500 000 patients with head and neck cancer (HNC) are diagnosed each year worldwide (1) . Despite comprehensive treatment strategies including surgery, radiotherapy and chemotherapy, approximately half of the patients with HNC die due to locoregional failure, distant metastases and second primary neoplasms (2) . Recurrent HNC (rHNC) and second primary neoplasms in the previously irradiated area represent a clinical challenge, and are normally treated with salvage surgical resection as this method offers the greatest probability for long-term survival (3) (4) . However, the population of candidates for curative salvage surgery is relatively small, and some patients require chemotherapy or re-irradiation in addition to surgery. The survival time after salvage chemotherapy has been estimated to be 6 months (5). Re-irradiation using a full dose is associated with severe toxicities including tissue necrosis, bleeding and infection, and treatment-related deaths due to carotid hemorrhage (6 -8) . Recent studies using intensity modulated radiotherapy (IMRT), stereotactic body radiotherapy (SBRT), twice-daily radiotherapy and concurrent chemotherapy reported the feasibility and effectiveness of re-irradiation in patients with rHNC (2, 7, 9) . These studies also reported locoregional control rates after re-irradiation ranging from 19 to 64%, and median survival times (MST) ranging from 8.5 to 28 months (1,8,10 -12) . Treatment outcomes vary widely due to heterogeneous patient characteristics and diverse treatment schedules. Moreover, an optimal salvage re-irradiation schedule has not yet been established (1, 8) . Optimal sub-classification according to a confidential prognostic index is essential to rigorously compare treatment outcomes. Tanvetyanon et al. (13) developed a nomogram to predict 2-year survival probability in patients with rHNC after salvage re-irradiation. The nomogram includes the following: the presence of comorbidities, organ dysfunction, presence or absence of isolated neck recurrence, tumor bulk and time interval between the previous radiotherapy and start of re-irradiation. The overall goal of the present study was to validate this nomogram in patients with rHNC who were mainly treated with SBRT.
PATIENTS AND METHODS
Twenty-eight consecutive patients with local rHNC who underwent salvage re-irradiation between June 2007 and November 2011 were evaluated. The male-to-female ratio was 20:8, with a median age of 65 years (range, 43 -90). Patients were treated for nasopharyngeal cancer (n ¼ 8), external ear cancer (n ¼ 4), hypopharyngeal cancer (n ¼ 3) and other cancers (n ¼ 13). Patient characteristics are shown in Table 1 . Initial radiotherapy included treatment with definitive radiotherapy (n ¼ 22), postoperative radiotherapy (n ¼ 5) and salvage radiotherapy (n ¼ 1) for recurrent disease after surgery. Twenty-three patients were treated with conventional three-dimensional external beam radiotherapy using Clinac iX or Trilogy (Varian Medical Systems, Inc., Palo Alto, CA) with a photon energy of 4 or 6 MV. Treatment plans included lateral opposed field, wedged pair field or multiple-field techniques. The radiation field covered the primary site, surrounding the lymph node area, and/or the prophylactic regional lymph node area. The prescribed dose was calculated at the center of the radiation field or from the planning target volume (PTV). The median total dose was 60 Gy (range, 48 -72) in 24 -36 fractions over a 5-to 7-week period. Five patients were treated with using robotic image-guided radiotherapy (Cyberknife Robotic Radiosurgery System; Accuracy, Inc., Sunnyvale, CA) with a median total dose of 38 Gy (range, 22 -39) in one to six fractions over a 1-to 6-day period. The prescribed dose for SBRT was defined as the dose covering at least 80% of the PTV. Sixteen patients received systemic chemotherapy concurrently or sequentially, which included platinum-based or 5-fluorouracil (5-FU) regimens ( Table 2 ). The median interval from initial radiotherapy to salvage re-irradiation was 9 months (range, 3 -40). Twenty-two patients had comorbidities and nine had organ dysfunction (e.g. tracheostomy and dysphagia) at the start of salvage re-irradiation. The median maximum diameter of recurrent disease was 3.4 cm (range, 1 -10). Re-irradiation sites included the nasopharynx or Rouviere's node (n ¼ 14), external ear (n ¼ 4), neck lymph node (n ¼ 3) and other sites (n ¼ 7). Twenty-two patients were treated with SBRT and six were treated with conventional external beam radiotherapy. The median total dose administered during salvage re-irradiation using SBRT was 30 Gy (range, 15 -40) in one to seven fractions over a 1-to 9-day period. The median total dose of salvage re-irradiation using conventional external beam radiotherapy was 45 Gy (range, 23.4 -60) in 10 -30 fractions over a 2-to 6-week period. Both re-irradiation techniques adopted narrow field margins without prophylactic regional lymph node irradiation. Three patients who were treated with conventional external beam radiotherapy received chemotherapy (i.e. platinum-based or 5-FU regimens) concurrently with radiotherapy.
The OS was calculated using the Kaplan -Meier method, and the median 2-year survival probability was estimated using the nomogram developed by Tanvetyanon et al. (13) The OS was measured from the start of re-irradiation and calculated using death due to any cause as an event. Tumor responses were classified as complete response (CR), partial response (PR), stable disease (SD) or progressive disease (PD) according to the revised Response Evaluation Criteria in Solid Tumors (revised RECIST guideline version 1.1) (14) . In-field recurrence was defined as an increase in the tumor size or appearance of new lesions in the re-irradiation area from diagnostic images, and out-field recurrence was defined as an increase in the tumor size or appearance of new lesions in the non-irradiated head and neck area. Distant metastases were defined as the appearance of new lesions beyond the head and neck area. Toxicity was assessed using the Common Terminology Criteria Adverse Event (CTCAE version 4.0). Statistical analyses were performed using JMP version 5.1J (SAS Institute, Inc.).
RESULTS
The median follow-up time in the present study was 7.3 months (range, 1.7225.3). After re-irradiation, 5 patients (18%) achieved CR, 8 (28%) achieved PR and 15 (54%) showed SD or PD. In addition, two patients achieving PR received salvage surgery and one patient achieving PR and three showing SD received systemic chemotherapy (i.e. Tegafur Gimeracil Oteracil Potassium, S-1). The other patients were carefully monitored and received supportive In patients who did not achieve RR, the median maximum tumor diameter was 3.7 cm (range, 1.5210.0; P ¼ 0.03).
MST after re-irradiation of patients who achieved RR was 13.3 months (95% CI, 6.0 -N/A) and 7.3 months for those who did not achieve RR (95% CI, 3.8-14.9; P ¼ 0.03).
Univariate analyses revealed that MST and 2-year OS of 19 patients with small recurrent disease ,4 cm were 13.0 months (95% CI, 6.0-N/A) and 26.6%, and those of 9 patients with large recurrent disease 4 cm or larger were 7.3 months (95% CI, 1.7 -N/A) and not applicable, respectively (P ¼ 0.39). MST and 2-year OS of 8 patients who developed recurrence within 6 months from the initial treatment were 7.9 months (95% CI, 1.7 -N/A) and 20.2%, and those of 18 patients who developed it beyond 6 months were 8.6 months (95% CI, 7.3 -18.9) and not applicable, respectively (P ¼ 0.62). MST and 2-year OS of 24 patients with good performance status (PS ¼ 0 -1) were 13.3 months (95% CI, 7.3 -N/A) and 24.9%, and those of 4 patients with poor PS (PS ¼ 2 -4) were 3.9 months (95% CI, 1.7 -N/A) and 0%, respectively (P ¼ 0.02).
The 2-year OS estimated using the Kaplan -Meier method was 21.7% (95% CI, 9.3 -41.3), and the MST was 8.6 months (95% CI, 6.0 -14.9; Fig. 1 ). The median 2-year survival probability estimated by Tanvetyanon's nomogram was 16.8% (95% CI, 9.9 -23.6). The 2-year OS in 20 patients with unfavorable prognosis whose 2-year survival probability was ,15% (median, 5.5; range, 1211) and the 2-year OS in eight patients with favorable prognosis whose 2-year survival probability was .15% (median, 45; range, 15255) was 11.0 and 45.7%, respectively (P ¼ 0.05; Fig. 2 ).
Two patients (7.1%) developed adverse events (Grades 223), which included tumor bleeding (Grade 2) and oral bleeding (Grade 3). In addition, three patients (10.7%) developed severe adverse events (Grade 5). All three patients developed local progression after re-irradiation, with two of them developing local infection and soft tissue necrosis in the submandibular area and paranasal cavity. These two patients died due to tumor progression and infection. The third patient was initially treated with whole neck conventional radiotherapy (60 Gy in 30 fractions) followed by adjuvant chemotherapy, and also received salvage SBRT (25.6 Gy in 5 fractions) to treat left-neck lymph node recurrence. Despite these treatments, the patient developed in-field recurrence 6 months later, which was treated with re-salvage SBRT (24 Gy in two fractions); however, recurrence was not controlled and the patient died eight months later due to a carotid artery rupture. Four patients who developed severe adverse events (Grades 325) were treated with Figure 1 . The overall survival curve (OS) of 28 patients with recurrent head and neck cancer (rHNC) was estimated using the Kaplan -Meier method. The white box shows the 2-year survival probability (16.8%) estimated using Tanvetyanon's nomogram. The vertical line indicates the 95% confidence interval of the 2-year OS rate (95% CI, 9.9 -23.6%). This figure shows approximate values for the 2-year OS calculated by the KaplanMeier method and the 2-year survival probability estimated by Tanvetyanon's nomogram. Figure 2 . OS curves of patients with rHNC with favorable and unfavorable prognoses. The 2-year OS in 20 patients with unfavorable prognosis whose 2-year survival probability was ,15% and the 2-year OS in eight patients with favorable prognosis whose 2-year survival probability was .15% were 11.0 and 45.7%, respectively (P ¼ 0.05).
re-irradiation using SBRT; however, there was no difference between re-irradiation modalities (P ¼ 0.25).
DISCUSSION
The American College of Radiology (ACR) Expert Panel on Head and Neck Cancer reviewed relevant literature on re-irradiation after definitive radiotherapy and evaluated its appropriateness, including radiation technique, treatment volume, doses and treatment schedule (3). The ACR Expert Panel emphasized the importance of patient selection and recommended careful evaluation and treatment by a comprehensive cancer team. Furthermore, they recommended considering re-irradiation with and without chemotherapy in patients with favorable prognosis and with relatively long estimated survival times. They also recommended performing a computed tomography (CT) scan of the chest and positron emission tomography/CT to determine the presence of metastatic disease, and evaluating patient conditions such as comorbidities, performance status, speech and swallowing function, and nutritional status. Moreover, a multi-disciplinary cancer care team should decide on the appropriate treatment strategy (e.g. salvage surgery, intensive re-irradiation with or without chemotherapy, chemotherapy alone and palliative care). The total absolute radiation dose to critical organs such as the spinal cord, carotid artery and optic pathways should be estimated using previous radiation dosimetry and latest patient images (8) . Another important consideration is the interval between previous radiotherapy and start of salvage re-irradiation. One study showed that a longer interval was associated with a lower probability of severe adverse events due to re-irradiation and lower occurrence rates of distant metastases (15) . In Tanvetyanon's nomogram, the interval is an important component used to estimate 2-year survival probabilities after re-irradiation (13) . Previously published clinical trials have used intervals of .6 months to determine the eligibility for re-irradiation (6,7). Hoebers et al. (15) reported that an interval of over 3 years was associated with a favorable OS. However, the appropriate interval between previous radiotherapy and re-irradiation remains unknown.
The Fox Chase Cancer Center conducted a phase I study (FCCC 96-006) combining twice-daily radiotherapy (1.5 Gy per fraction bid; 5 days every other week; four cycles) with concurrent cisplatin and paclitaxel administration during salvage therapy (16) . The MST was 9.5 months, and the 1-and 2-year OS were 41 and 27%, respectively. Hematologic toxicities were feasible, and grade 3 mucositis occurred in only 6% of patients. Given these encouraging results, the Radiation Therapy Oncology Group (RTOG) conducted a phase II study (RTOG 9911) to evaluate the efficacy and toxicity of twice-daily radiotherapy (1.5 Gy per fraction bid; 5 days every other week; four cycles) with concurrent cisplatin and paclitaxel administration (6) . One-hundred and five patients were enrolled into the study, and 1-and 2-year OS were 50.2 and 25.9%, respectively. These findings suggest that this strategy is a promising treatment option; however, eight treatment-related deaths (8%), including acute neutropenic sepsis and late carotid hemorrhage, were noted. Spencer et al. (17) conducted a phase I study on previously irradiated patients with rHNC who received hydroxyurea and 5-FU in combination with daily radiotherapy (2 Gy per fraction) during a 2-week period followed by a 1-week break. These patients then received hyperfractionated radiotherapy on weeks 4 and 5 (total dose 50 Gy). The 1-and 2-year OS were 41 and 15%, respectively, and one patient died 3 weeks after the study due to pneumonia. Furthermore, two patients acquired soft tissue ulcers, and one developed trismus and a non-healing clavicular fracture. Therefore, concurrent chemoradiotherapy using twice-daily regimens are not considered ideal strategies for re-irradiation (18).
Hoebers et al. (15) evaluated 58 patients who had received re-irradiation at a median cumulative dose of 119 Gy (range, 762140) with or without chemotherapy. The group reported a 2-year OS of 42%, and that higher re-irradiation doses and concurrent chemoradiation were associated with severe adverse events. They also reported that re-irradiation alone (compared with concurrent chemo-re-irradiation), a longer interval between initial radiotherapy and salvage re-irradiation, and a lower cumulative radiation dose were associated with better local control rates. Lee et al. (4) reported a study of 105 patients with rHNC who received re-irradiation with or without chemotherapy. The multivariate analyses revealed that non-nasopharynx and non-IMRT were associated with an increased risk of locoregional failure. Administration of chemotherapy could not be used to predict improved locoregional control rates and OS. The role of concurrent or sequential chemotherapy remains uncertain for re-irradiation in patients with rHNC. In the present study, 83% of patients with progressive disease after re-irradiation developed in-field recurrence with or without distant metastases. Lee et al. (4) reported the occurrence of locoregional failure with or without distant metastases in 65% of patients who developed progressive disease after re-irradiation. They also emphasized that future efforts for maximizing tumor control in a recurrent setting, including dose escalation with IMRT and effective chemotherapy, were warranted. The median re-irradiation dose of 45 Gy in our conventional radiotherapy is low compared with previously published doses. We could not use IMRT then for head and neck cancers in our institute, and thus relatively low re-irradiation doses were used to avoid the risk of high radiation exposure of organs. As it is now possible to use IMRT, more aggressive radiation therapy should be tried in the salvage setting.
Stereotactic radiotherapy, such as single fraction stereotactic radiosurgery (SRS) and fractionated SBRT using concave dose distributions, is useful since it protects critical organs (e.g. carotid artery, spinal cord, brain stem and optic pathway). The University of Pittsburgh conducted a phase I dose-escalation study in patients with rHNC. The results revealed that 44 Gy in five fractions over a 2-week period was (4) reported that IMRT was better suited to predict locoregional tumor control. New technologies such as stereotactic radiotherapy (SRT), SBRT and IMRT might be useful tools to increase the prescribed dose without incrementing the exposure to critical organs. In our study, 79% of patients received SRT/SBRT and the majority developed minor recurrent disease. The most frequent recurrence after re-irradiation occurred within the re-irradiation field. However, our findings did not highlight the superiority of SRT/SBRT, and it did not clarify what the appropriate modality and radiation schedule should be. Unger et al. (19) reported a study on 65 patients who received a median initial radiotherapy of 67 Gy and a median re-irradiation SBRT dose of 30 Gy (range, 21235) in two to five fractions. They reported that the 2-year OS and locoregional control rates were 41 and 30%, respectively. In addition, they showed by multivariate analysis that a higher total dose, surgical resection and naopharynx site were significantly associated with an improved locoregional control rate. Surgical resection and non-squamous histology were also associated with an improved OS (19) . However, 11% of patients in that study experienced severe toxicities due to re-irradiation. Lee et al. (4) reported that a nasopharyngeal site and IMRT technique were associated with a good locoregional progression-free survival (LRPFS) in patients with rHNC who received re-irradiation. Finally, they concluded that achieving locoregional control was crucial to improve OS and that radiation doses .50 Gy were associated with better LRPFS and OS. The present study has a few limitations worth noting. First, this study is a retrospective review of patients from a single institution, and thus selection-and physician-based biases may exist. In addition, it is important to note that the results are based on a small number of patients who underwent diverse radiotherapy schedules. Secondly, a minority of patients received conventional external beam re-irradiation, whereas no patients received IMRT. Finally, the median follow-up time in the study was only 7.3 months (range, 1.7225.3). Longer follow-up periods are needed to clarify the long-term complications associated with re-irradiation.
CONCLUSION
Our results suggest that Tanvetyanon's nomogram accurately estimates survival probability after salvage re-irradiation in patients with rHNC. This nomogram is a practical tool for optimal sub-classification of patients with rHNC to evaluate treatment outcomes. Future prospective studies using this nomogram should be performed to establish the appropriate re-irradiation schedule for these patients.
